
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Argenx SE - ARGX
NEW YORK, July 7, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of argenx SE ("argenx" or the "Company") (NASDAQ: ARGX ). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether argenx and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On June 30, 2025, the U.S. Food and Drug Administration ("FDA") issued an alert on a potential signal of serious risks associated with argenx's Vyvgart Hytrulo product, stating that the treatment has a potential risk of "severe worsening of chronic inflammatory demyelinating polyradiculoneuropathy" based on reports to the FDA Adverse Event Reporting System. The alert also said that the "FDA is evaluating the need for regulatory action."
On this news, argenx's American Depositary Share ("ADS") price fell $8.92 per ADS, or 1.59%, to close at $551.22 per ADS on June 30, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See .
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE? 440k+Newsrooms &
Influencers 9k+
Digital Media
Outlets 270k+
Journalists
Opted In GET STARTED

Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research

- SPAYZ.Io White Paper Explores Opportunities, Challenges And Ambitions In Payments Industry
- Ethereum-Based Defi Crypto Mutuum Finance (MUTM) Reaches 50% Completion In Phase 6
- Currency Relaunches Under New Leadership, Highlights 2025 Achievements
- Izumi Finance And Nasdaq-Listed Company CIMG Co-Launch $20M Upstarts Fund
- Tradesta Becomes The First Perpetuals Exchange To Launch Equities On Avalanche
- Bydfi Highlights 'BUIDL' Ethos During Newcastle United Match Against Arsenal
Comments
No comment